Distribution and Prognostic Significance of Estrogen Receptor α (ERα), Estrogen Receptor β (ERβ), and Human Epidermal Growth Factor Receptor 2 (HER-2) in Thyroid Carcinoma
Table 2
Clinicopathologic correlation of ERβ.
Sl no.
Attribute
ERβ positive (n = 58)
ERβ negative (n = 206)
valuea overall
valuea PTC
valuea FTC
valuea PDTC
1.
Age in years (mean ± SD)
45.9 ± 14.2
46.2 ± 15.9
0.865
0.371
0.707
0.086
2.
Gender (M : F)
19 : 39
71 : 135
0.876
0.305
0.507
0.014
3.
Presence of PDAb, n (%)
11 (24.4)
79 (43.2)
0.026
1.000
0.212
—
4.
Tumor size in cm (mean ± SD)
4.9 ± 3.1
4.6 ± 2.7
0.540
0.807
0.279
0.068
5.
Multicentricity, n (%)
15 (26.3)
55 (27.4)
1.000
0.679
0.668
0.389
6.
Extrathyroidal extension, n (%)
18 (31.0)
47 (23.3)
0.233
1.000
1.000
1.000
7.
Lymph node metastases, n (%)
31 (53.4)
71 (34.6)
0.014
0.836
0.117
0.310
8.
Metastases, n (%)
18 (31.0)
65 (31.9)
1.000
0.513
0.369
0.299
9.
Recurrence, n (%)
7 (12.0)
18 (8.7)
0.445
0.550
0.158
0.305
10.
Mean survival in months (n ± SE)
127 ± 8.5
197 ± 6.9
0.400
0.956
0.069
0.638
aAll values obtained on univariate analysis. b PDA, poorly differentiated areas. Significant positive correlation of ERβ expression and occurrence of PDTC in females. Significant negative correlation of ERβ expression and occurrence of PDA. Significant positive correlation of ERβ expression and incidence of lymph nodal metastases.
